Posts Tagged ‘competition’

Tirzepatide Pricing Comes in Similar to Semaglutide

May 21, 2022 — Competition can be a great thing. In the past few weeks we’ve been hearing a lot about tirzepatide. The FDA just approved it for treating type 2 diabetes, hailing it as an important advance. Tirzepatide for obesity is a couple of years away, but the initial results of pivotal studies have been extremely impressive. So […]

FDA Approves “An Important Advance,” Tirzepatide

May 14, 2022 — Yesterday, FDA approved tirzepatide for type 2 diabetes, calling it “an important advance.” The brand name will be Mounjaro. This is the same drug for which its maker, Eli Lilly and Company, announced remarkable results in a phase 3 obesity study barely two weeks ago. It is the first of its kind – a dual […]

Racing Toward Better Anti-Obesity Medicines

February 9, 2022 — There’s a race heating up. It is a race to open the way for better obesity care and deliver better options. In this race, semaglutide (Wegovy™) has a head start. But a pack of other options are on the way. Yesterday in JAMA, results in a study of tirzepatide for treating type 2 diabetes tell […]

Innovation and Competition in Obesity Gains Momentum

August 9, 2021 — Could it be that innovation and competition for better obesity care will overtake the health problem of obesity? We see several signs pointing to this. A decade ago, it was tough to get FDA to take obesity innovation seriously. So big pharma research was running from the challenge. Sanofi had invested heavily in developing rimonabant […]

Tirzepatide and the Search for Better Obesity Treatment

February 22, 2021 — When NEJM recently published impressive results for a new obesity treatment, it caused quite a stir. Now it looks like semaglutide might have some serious competition coming right behind it. Late last week, Lilly announced results for two phase 3 studies of tirzepatide. These were both studies for type-2 diabetes. Effects on body weight were […]